Increase in share capital
Oslo, 8 April 2013
Reference is made to the stock exchange announcement dated 2 April 2013 regarding the resolution by the extraordinary general meeting in DiaGenic ASA (the "Company", ticker "DIAG") to increase the share capital in the Company following the private placement comprising the issuance of 50,000,000 new shares.
The share capital increase pertaining to the private placement has now been registered with the Norwegian Register of Business Enterprises. The new registered share capital of DiaGenic is NOK 38,511,826 divided into 77,023,652 shares, each with a nominal value of NOK 0.50 and gives the right of one vote at the Company’s general meeting. The new shares will be immediately listed on Oslo Børs.
For further information, please contact:
Henrik Lund, Chairman, DiaGenic ASA, Phone +47 90 97 12 19
Paul de Potocki, CEO, DiaGenic ASA, Phone +47 23 24 89 67
Denne informasjonen er informasjonspliktig i henhold til verdipapirhandelloven § 5-12.
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com